APA (7th ed.) Citation

Liu, X., Zhuang, C., Liu, L., Xiong, L., Xie, X., He, P., . . . Luo, T. Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): Efficacy, safety and biomarker analysis. Nature Publishing Group.

Chicago Style (17th ed.) Citation

Liu, Xiaoxiao, et al. Exploratory Phase II Trial of an Anti-PD-1 Antibody Camrelizumab Combined with a VEGFR-2 Inhibitor Apatinib and Chemotherapy as a Neoadjuvant Therapy for Triple-negative Breast Cancer (NeoPanDa03): Efficacy, Safety and Biomarker Analysis. Nature Publishing Group.

MLA (9th ed.) Citation

Liu, Xiaoxiao, et al. Exploratory Phase II Trial of an Anti-PD-1 Antibody Camrelizumab Combined with a VEGFR-2 Inhibitor Apatinib and Chemotherapy as a Neoadjuvant Therapy for Triple-negative Breast Cancer (NeoPanDa03): Efficacy, Safety and Biomarker Analysis. Nature Publishing Group.